Thursday 16 October, 2025
Objectives: PSA monitoring is used to detect cancer relapse after prostatectomy. PSA doubling time (PSADT) is a useful concept to…
Read morePoster: Other Drug/Disease Modelling
Is it possible to use the plasma and urine pharmacokinetics of a monoclonal antibody (mAb) as an early marker of efficacy in membranous nephropathy (MN)?
Thursday 16 October, 2025
Objectives: Renal clearance is typically not considered to be a major pathway of elimination of monoclonal antibody (mAb) due to…
Read moreHow to improve the prediction of Sustained Virologic Response (SVR) for Hepatitis C patients using early Viral Load (VL) Information
Thursday 16 October, 2025
Objectives: In clinical drug development of Chronic Hepatitis C treatments, early VL information between week 2 and week 8 (e.g.:…
Read moreIdentification of a dual mechanism of action (MoA) for Danoprevir (DNV), a protease inhibitor currently in phase 2, using a mechanistic viral kinetic model
Thursday 16 October, 2025
Objectives: DNV is an inhibitor of the HCV NS3/4A protease that has potent activity against HCV, and is currently in…
Read morePopulation Pharmacokinetic Analysis of Canagliflozin, an Orally Active Inhibitor of Sodium-Glucose Co-Transporter 2 (SGLT2) for the Treatment of Patients With Type 2 Diabetes Mellitus (T2DM)
Thursday 16 October, 2025
Objectives: Canagliflozin, an orally active inhibitor of SGLT2, is currently in development for the treatment of patients with T2DM. The…
Read more